Displaying items by tag: verve study

You may qualify to participate in a national research study to evaluate the safety and effectiveness of the shingles vaccine (Zostavax®). Are you at least 50 years old? Are you taking Remicade, Enbrel, Humira, Cimzia or Simponi? If yes, and if you have never received the shingles vaccine, you may qualify. The duration of the study is 6 months. Participants will be compensated. Zostavax ® is an approved vaccine for people ages 50 and older and has been shown to be very effective to prevent zoster (shingles) and related complications. However it has NOT been studied in patients who are taking Remicade, Enbrel, Humira, Cimzia or Simponi. The Varicella zostER VaccinE Study (VERVE) has been approved by the Food and Drug Administration (FDA). UAB is coordinating the VERVE study. For more information, please call (205) 934-2993 or email verve@uab.edu